01. Product portfolioProTransStudy TeamCellaviva
02. About NextCellBusiness ConceptVision, mission, strategyHistory
OrganisationCompany Structure
03. InvestorsExtraordinary General Meeting 2026NextCell as an investmentFinancial CalendarFinancial ReportsCorporate GovernanceCertified AdviserThe ShareArchive
04. NewsPress ReleasesNextCell in the mediaEventsCompany PresentationsQ&A with CEO
05. ContactContact InformationSubscribe
English
/
Svenska

NextCell Participating in JETRO’s Japan Entry Acceleration Program

February 17, 2026

NextCell Pharma AB (“NextCell” or the “Company”) announces its participation in the Japan Entry Acceleration Program (“JEAP”) in regenerative medicine, an international accelerator initiative organized and funded by JETRO. NextCell is communicating its participation in connection with the Company’s current presence in Tokyo, where program activities and meetings with Japanese industrial, regulatory and financial stakeholders are now taking place.

JEAP operates a global and highly selective admission process. NextCell was selected in competition with companies from leading life science markets in North America and Europe and is one of only a few European companies admitted to the regenerative medicine track. Selection is based on scientific excellence, clinical relevance and commercial potential in the Japanese market.

The program is designed to support international regenerative medicine companies seeking to establish partnerships in Japan. It includes market and regulatory workshops, tailored mentorship, and structured matchmaking with Japanese pharmaceutical companies, CDMOs, CROs and investors. The program concludes with a Demo Day in Tokyo, where participating companies present their technologies and strategic plans to industry and financial representatives. Participation in JEAP is fully funded and includes coverage of travel and accommodation within the framework of the program.

NextCell’s participation aligns with the Company’s previously communicated strategy to gradually establish regional platforms in Asia through internationally recognized and regulatorily robust markets. In January 2026, NextCell announced a strategic update highlighting Hong Kong as an initial gateway to Asia and, over time, Mainland China. In parallel, the Company is strengthening its presence in Japan, a market characterized by high scientific standards, clear regulatory pathways and a well-developed ecosystem for advanced therapies and cell and gene therapy.

“Our participation in JEAP represents a concrete step in the execution of NextCell’s Asia strategy. Being present in Japan enables structured discussions with potential partners across development, manufacturing and commercialization of ProTrans,” says Mathias Svahn, CEO.

About JETRO

Japan External Trade Organization (JETRO) is a government-supported organization with a mission to promote trade and investment between Japan and the rest of the world. JETRO runs several international programs to support foreign companies in strategic growth areas, including regenerative medicine and advanced therapies.

For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Eric Gustafsson, CFO
Tel: +46 8 735 5595
E-mail: info@nextcellpharma.com

Websites:
NextCell Pharma AB: www.nextcellpharma.com
Cellaviva Sverige: www.cellaviva.se
Cellaviva Danmark: www.cellaviva.dk
QVance AB: www.qvance.se

LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma

Certified Adviser

The company's shares are listed on the Nasdaq First North Growth Market.
RedEye Sweden AB is the company´s Certified Adviser.

About NextCell Pharma AB
NextCell Pharma is a clinical-stage cell therapy company developing ProTrans, a patent-protected platform based on allogeneic mesenchymal stromal cells (MSCs) from umbilical cord tissue. Using a proprietary selection algorithm, ProTrans delivers optimised cell tailored to specific indications.  In type 1 diabetes, a single infusion has been shown to preserve insulin production and delay disease progression for at least five years.  A Phase III trial is planned to commence upon securing a commercial partner. ProTrans is also being evaluated for other autoimmune and inflammatory conditions. NextCell’s subsidiaries include Cellaviva, Scandinavia’s largest private stem cell bank, and QVance, the Nordic region’s first dedicated provider of quality services for developers of advanced therapies.

Download attachmentRead full press release on Cision (external link)
2020-06-24
NextCell Pharma AB’s rights issue heavily oversubscribed
The Board of Directors of NextCell Pharma AB ("NextCell" or the “Company”) announces today the outcome in the Company’s new issue of shares with preferential rights for existing shareholders (the “Rights Issue”). The demand was high and the Rights Issue was oversubscribed. Thus, no guarantees have been utilized. Through the Rights Issue, the Company receives approximately SEK 25.1 million before transaction costs. · 4,111,192 shares were subscribed using subscription rights · In addition, applications for subscription without using subscription rights corresponding to 11,750,102 shares
The Board of Directors of NextCell Pharma AB ("NextCell" or the “Company”) announces today the outcome in the Company’s new issue of shares with preferential rights for existing shareholders (the “Rights Issue”). The demand was high and the Rights Issue was oversubscribed. Thus, no guarantees hav...
Read moreRead more
2020-06-09
NextCell's phase II study is completed – a phase III is being prepared
NextCell Pharma AB ("NextCell") announces that the last patient now has left ProTrans-2, meaning the phase II trial with the drug candidate ProTrans for treatment of type 1 diabetes, is completed according to plan. Data will be compiled and analyzed by independent statistician to be presented during the third quarter. “NextCell is now preparing a phase III trial in order to reach the market as soon as possible, in case of a positive result of the phase II study”, says Mathias Svahn, CEO. NextCell's drug candidate, ProTrans ™, developed for the treatment of type 1 diabetes, has, in
NextCell Pharma AB ("NextCell") announces that the last patient now has left ProTrans-2, meaning the phase II trial with the drug candidate ProTrans for treatment of type 1 diabetes, is completed according to plan. Data will be compiled and analyzed by independent statistician to be presented dur...
Read moreRead more
2020-06-03
NextCell Pharma AB publishes prospectus relating to the rights issue and announces the intention of change of listing to Nasdaq First North in July
The Board of Directors of NextCell Pharma AB ("NextCell" or the “Company”) has prepared a prospectus (the “Prospectus”) relating to the new issue of shares with preferential rights for existing shareholders of approximately SEK 25.1 million (the Rights Issue”), which was resolved by the Board of Directors on 15 May 2020 and approved by the extraordinary general meeting on 3 June 2020. The Prospectus has today been approved and registered by the Swedish Financial Supervisory Authority. Today, the Company also announces the intention of change of listing. The Company has obtained conditional
The Board of Directors of NextCell Pharma AB ("NextCell" or the “Company”) has prepared a prospectus (the “Prospectus”) relating to the new issue of shares with preferential rights for existing shareholders of approximately SEK 25.1 million (the Rights Issue”), which was resolved by the Board of ...
Read moreRead more
2020-05-28
Invited to panel discussion; Post-Covid-19 world
NextCell Pharma AB ("NextCell") has been invited to participate in the panel discussion entitled “The impact of corona virus on the global healthcare - new challenges and main problems”. Doctor Lindsay Davies, Chief Scientific Officer at NextCell and researcher at Karolinska Institutet will join the panel. Today, 28[th] of May, international experts are having a one-day video conference. The conference is hosted by the Polish Medical Research Agency, Ministry of Health, Ministry of Development and is organized by the Kulski Foundation. The panel discussion is at 15:15 with opening speech
NextCell Pharma AB ("NextCell") has been invited to participate in the panel discussion entitled “The impact of corona virus on the global healthcare - new challenges and main problems”. Doctor Lindsay Davies, Chief Scientific Officer at NextCell and researcher at Karolinska Institutet will join ...
Read moreRead more
2020-05-15
The Board of Directors of NextCell Pharma AB resolves on a fully guaranteed SEK 25.1 million rights issue
NextCell Pharma AB ("NextCell" or the “Company”) announces that the Board of NextCell Pharma AB has resolved to conduct a fully guaranteed new issue of shares of approximately SEK 25.1 million with preferential rights for the Company's existing shareholders (the "Rights Issue"), subject to approval by an extraordinary general meeting in the Company. The Company’s largest shareholder Diamyd Medical AB and chairman of the Boad of Directors Anders Essen-Möller have undertaken to subscribe for their pro rata share in the Rights Issue. In total, the Rights Issue is covered by subscription
NextCell Pharma AB ("NextCell" or the “Company”) announces that the Board of NextCell Pharma AB has resolved to conduct a fully guaranteed new issue of shares of approximately SEK 25.1 million with preferential rights for the Company's existing shareholders (the "Rights Issue"), subject to approv...
Read moreRead more
2020-04-29
NextCell Pharma AB publishes its interim report for September 2019 - February 2020
NextCell Pharma AB (publ) (NXTCL) today announces that its Interim report for the period September 1, 2019 - February 29, 2020 now is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-reports Second quarter (2019-12-01 until 2020-02-29) · Operating income amounted to SEK 1 364 645 (435 051). · Operating result amounted to SEK -4 228 449 (-3 552 444). · Earnings per share* amounted to SEK -0,22 (-0,31). · Cash and bank amounted to SEK 10 700 725 (6 886 879). · Solidity** amounted to 80,2 (85,0) %. First six month (2019-09-01
NextCell Pharma AB (publ) (NXTCL) today announces that its Interim report for the period September 1, 2019 - February 29, 2020 now is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-reports Second quarter (2019-12-01 until 2020-02-29) · Operating income...
Read moreRead more
2020-03-20
NextCell in discussions about patients with covid-19
NextCell Pharma AB ("NextCell") announces that parallel discussions with several hospitals have been initiated to treat patients with covid-19, the severe respiratory tract infection caused by the new coronavirus, with the stem cell product ProTrans. “We would like to emphasize that this information is preliminary. There are both administrative and regulatory challenges, but the intention from healthcare is to go forward with this. We will come back when and if further information is available, says Mathias Svahn, CEO of NextCell. "We advise against speculative share purchases in the
NextCell Pharma AB ("NextCell") announces that parallel discussions with several hospitals have been initiated to treat patients with covid-19, the severe respiratory tract infection caused by the new coronavirus, with the stem cell product ProTrans. “We would like to emphasize that this informa...
Read moreRead more
2020-03-11
The stem cell company NextCell Pharma is preparing for a pivotal phase III trial
NextCell Pharma AB ("NextCell") announces that CEO Mathias Svahn will present a status update of the ongoing clinical trials at the Stockholm Corporate Finance Life Science Seminar held at Berns in Stockholm today, March 11. NextCell Pharma is currently running two parallel trials with ProTrans (Protrans-1 Phase I/II and ProTrans-Repeat) for the treatment of patients with type 1-diabetes. Ten out of a total of 15 patients in the phase II part of ProTrans-1 (ProTrans 2) have now left the trial and the last patient's last visit is scheduled for the end of June/July 2020. Thereafter, data will
NextCell Pharma AB ("NextCell") announces that CEO Mathias Svahn will present a status update of the ongoing clinical trials at the Stockholm Corporate Finance Life Science Seminar held at Berns in Stockholm today, March 11. NextCell Pharma is currently running two parallel trials with ProTrans (...
Read moreRead more
This website uses cookies in order to improve the user experience. Read more
Preferences
DenyAccept